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Abstract
Background Circulating tumour cells (CTCs) are attractive “liquid biopsy” candidates that could provide insights into
the different phenotypes of tumours present within a patient. The epithelial-to-mesenchymal transition (EMT) of CTCs is
considered a critical step in tumour metastasis; however, it may confound traditional epithelial feature-based CTC isolation
and detection. We applied single-cell copy number alteration (CNA) analysis for the identification of genomic alterations to
confirm the neoplastic nature of circulating cells with only mesenchymal phenotypes.
Methods We isolated CTCs from blood samples collected from 46 NSCLC patients using the Parsortix system. Enriched cells
were subjected to immunofluorescent staining for CTC identification using a multi-marker panel comprising both epithelial
and mesenchymal markers. A subset of isolated CTCs was subjected to whole genome amplification (WGA) and low-pass
whole-genome sequencing (LP-WGS) for the analysis of copy number alterations (CNAs).
Results CTCs were detected in 16/46 (34.8%) patients, inclusive of C
 K+/EpCAM+ CTCs (3/46, 6.5%) and Vim+ CTCs
(13/46, 28.3%). Clusters of Vim+ cells were detected in 8 samples, which constitutes 50% of the total number of NSCLC
patients with CTCs. No patients had detectable hybrid CK+/EpCAM+/Vim+ cells. All of the tested CK+/EpCAM+ CTCs and
7/8 Vim+ CTCs or CTC clusters carried CNAs confirming their neoplastic nature. Notably, the Vim+ cluster with no CNAs
was characterised by spindle morphology and, therefore, defined as normal mesenchymal circulating cells.
Conclusion Our results revealed that CK-negative, vimentin-expressing cells represent a large proportion of CTCs detected
in NSCLC patients, which are likely missed by standard epithelial-marker-dependent CTC categorisation.
Keywords Circulating tumour cells · Epithelial-to-mesenchymal transition · Vimentin · Single-cell sequencing · Non-small
cell lung cancer
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Lung cancer is the worldwide leading cause of cancer
mortality, with an estimated number of deaths reaching
1.8 million in 2020 alone (Sung et al. 2021). Non-small
cell lung cancer (NSCLC) accounts for 80–85% of lung
cancer cases (Zappa and Mousa 2016). NSCLC patients
are typically diagnosed at an advanced stage, and the estimated 5-year survival rate for NSCLC is 26.4% (Ganti
et al. 2021). Immunotherapy has revolutionised the treatment paradigm of NSCLC, significantly prolonging the
overall survival of advanced-stage patients (Chiang and
Herbst 2020; Berghmans et al. 2020). Despite the striking
clinical improvement with immunotherapies, the majority
of patients eventually fail to respond to these drugs due to
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the evolution of primary or secondary resistance (Borghaei
et al. 2015; Brahmer et al. 2012).
Unravelling aggressive tumour cell phenotypes as they
evolve during treatment can provide predictive insights
into the occurrence of resistance to standard of care treatments. Circulating tumour cells (CTCs) have emerged as
a minimally invasive “liquid biopsy” strategy that has particular relevance for NSCLC due to the complexities of
obtaining a lung biopsy (Alix-Panabières and Pantel 2016;
Keller and Pantel 2019). CTCs are tumour-derived cells
shed from diverse neoplastic deposits in the bloodstream
(Keller and Pantel 2019; Alix‐Panabières and Pantel
2017). As such, CTCs mirror tumour heterogeneity of both
primary tumours and their metastases, making them excellent candidates that reflect the phenotypes of all lesions
present within a patient at any one time (Hanssen et al.
2015). Moreover, while it is difficult in clinical practice
to obtain repeat biopsies from any lesion, CTCs acquired
through a sample of blood could be used as a source of
information on the tumour tissue over time (Lucci et al.
2012).
Historically, analyses of CTCs mainly focused on cells
expressing epithelial phenotype-specific markers, such as
pan-cytokeratin (pCK) and epithelial adhesion molecule
(EpCAM) for immunofluorescent identification (Cote and
Datar 2016; Maly et al. 2019). Classical NSCLC CTCs are
defined by an intact nucleus, expression of pCK and EpCAM
which show the epithelial origin of the cells, and absence of
CD45, indicating the cell is not of a hematopoietic lineage
(Krebs et al. 2012). However, the epithelial-to-mesenchymal transition (EMT) is a key process for cells to leave the
tumour and migrate into circulation. During this process,
epithelial makers are down-regulated concomitantly with the
upregulation of mesenchymal markers such as vimentin and
N-cadherin (Tania et al. 2014; Bartis et al. 2014). Hence,
mesenchymal cells may be missed when CTC isolation and
identification are based only on epithelial features (Xu et al.
2015). This is particularly relevant for NSCLC, given that
some studies have reported the presence of CTCs with mesenchymal features in patients affected by this malignancy
(Li et al. 2020; Lecharpentier et al. 2011; Ciccioli et al.
2021). To overcome this challenge, we employed a novel
epitope-independent isolation method using the Parsortix, a
microfluidic device which captures CTCs based on the larger
size and less deformable nature of tumour cells compared to
normal blood cells (Chudziak et al. 2016).
By combining microfluidic enrichment for NSCLC CTCs
together with immunofluorescence, we identified circulating
cells with mesenchymal features in NSCLC patient samples. However, studies have not provided direct proof of the
neoplastic nature of such mesenchymal cell subpopulations.
We applied single-cell copy number alteration (CNA)
analysis for the identification of genomic alterations to
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confirm the neoplastic nature of these circulating cells with
mesenchymal phenotypes.

Materials and methods
Patient recruitment and sample collection
A total of 46 NSCLC patients at Sir Charles Gairdner Hospital (SCGH) and Fiona Stanley Hospital (FSH) in Perth,
Western Australia, were prospectively recruited between
August 2018 and October 2021 before commencing treatment. Written informed consent was obtained from all
patients and procedures were approved by Human Research
Ethics Committees at Edith Cowan University (No.
18957) and Sir Charles Gairdner Hospital (No. 2013-246,
RGS0000003289) in compliance with the Declaration of
Helsinki. Experiments were conducted per institutional and
national guidelines and regulations. For CTC quantification,
at least 8 mL of blood from each subject was collected in
vacutainer K2EDTA tubes (BD Biosciences, East Rutherford, NJ), following the collection of a serum tube to remove
any potential contaminating epithelial or endothelial cells.
Samples were processed within 6 h of blood collection.

CTC isolation and identification
CTCs were enriched using the Parsortix system (Angle
plc, Guildford, UK). Enriched cells were harvested according to the manufacturer’s instructions and fixed for 10 min
at room temperature (RT) with 2% PFA. Following this,
enriched cells were cytospun using Cytospin 4 (Thermo
Fisher Scientific) onto glass slides at 2000 rpm for 5 min.
For CTC identification, enriched cells were immunofluorescently stained based on a protocol developed in our lab
(Spencer 2020). Fixed samples were fluorescently labelled
with Alexa Fluor (AF) 488 and FITC-conjugated antibodies
against epithelial markers (pan-cytokeratins and EpCAM),
phycoerythrin (PE)-conjugated white blood cell (WBC)
markers (CD45 and CD16) to exclude hematopoietic cells,
an anti-PD-L1 antibody (28.8-AF647) for PD-L1 expression and 4′,6-diamidino-2-phenylindole (DAPI) for nuclear
staining (Table S1). CTCs were defined as CK+/EpCAM+/
CD45−/16− with a DAPI+ nucleus. For mesenchymal marker
expression analysis, previously stained slides underwent
fluorescence quenching with an established protocol using
sodium borohydride (Adams et al. 2016; Manjunath et al.
2019; Spencer 2020). This protocol allows multi-phenotypic subtyping of CTCs utilising sequential fluorescent
quenching and re-staining for further biomarkers (Adams
et al. 2016; Acheampong et al. 2022). Following quenching of fluorescence from the initial round of immunostaining, samples were re-stained with mesenchymal markers
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(vimentin-AF647, and N-cadherin-PE). Slides were visualised and scanned using an Eclipse Ti-E inverted fluorescent
microscope (Nikon, Chiyoda, Japan). Images were analysed
using the NIS-Elements Analysis software, version 5.21
(Nikon).

Characterisation of enriched cells at the single‑cell
level
To confirm the malignant nature of the putative CTC populations by detecting genome-wide CNAs, the CellCelector (ALS, Jena, Germany) platform was employed to pick
individual pCK and vimentin (Vim) only expressing cells
from stained slides, previously optimised in our lab (Beasley
et al. 2018). Picked cells were subjected to whole-genome
amplification (WGA) using the Ampli1 WGA Kit (Silicon
Biosystems, Bologna, Italy) according to the manufacturer’s
specifications. Quality control of WGA-DNA was performed
using Ampli1 QC Kit following the manufacturer’s instructions (Silicon Biosystems). WGA-DNA was used to construct 400 bp sequencing libraries using the Ampli1 LowPass Kit for Ion Torrent (Silicon Biosystems) following the
manufacturer’s instructions. Pooled library was diluted to
50 pM and loaded into an Ion 530 Chip (Life Technologies)
using the Ion Chef (400 base chemistry) (Life Technologies)
and sequenced on an Ion S5 (Life Technologies) for 525
flows. CNAs were analysed using the Ion Reporter Software
(Life Technologies).

Statistical analysis
Demographic data were presented as numbers, ranges,
counts, percentages, means, and medians. The graph for
CTCs counts was processed using GraphPad Prism version
8.0.2. The primary endpoints of the outcome analysis were
overall survival (OS) and progression-free survival (PFS).
Kaplan–Meier method was used to estimate median OS
and PFS within groups and differences in patient survival
rates were determined using log-rank tests. Univariate Cox
regression hazard model for OS was performed for age, sex,
NSCLC stage, ECOG performance status, histological type,
tumour PD-L1 expression, treatment, and CTC counts. All
survival analyses were performed in R version 4.05 using the
package “survplot”. P values less than 0.05 were considered
statistically significant.

Results
Demographics of patients
The patient demographics are summarised in Table 1.
The median age of patients was 72 years. Majorities of

Table 1  Patient characteristics
Variables

n = 46

Age, years (median, IQR)
Age group (years)
< 70
≥ 70
Sex
Male
Female
ECOG status
0
1
2
Unknown
Smoking status
Smoker
Non-smokers
Unknown
Histological type
Adenocarcinoma
Squamous cell carcinoma
Others
Stage
IIIB
M1a
M1b
M1c
Molecular status
KRAS mutant
No detection
Unknown
Treatment
IO
Chemotherapy + IO
None
Tumour PD-L1 expression (%)
<1
1–49
≥ 50
Undetermineda

72 (64–76)

%

18
28

39.1
60.9

30
16

65.2
34.8

19
13
13
1

41.2
28.3
28.3
2.2

44
1
1

95.6
2.2
2.2

36
8
2

78.3
17.4
4.5

1
12
5
28

2.2
26.1
10.9
60.8

14
20
12

30.4
43.5
26.1

16
27
3

34.8
58.6
6.5

11
13
17
5

2.9
28.3
36.9
10.9

ECOG Eastern Cooperative Group, IO immunotherapy, IQR interquartile range
a

Undetermined due to insufficient tumour material

the patients were male (65.2%), had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1
(69.5%), and were smokers (95.6%). Most patients had stage
IV M1c NSCLC (60.8%), and adenocarcinoma was the most
histological type (78.3%) among patients. Fourteen patients
had tumours with KRAS mutations (30.4%). Information on
tumour PD-L1 expression was available for most patients,
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with vimentin and N-Cadherin. Different CK+/EpCAM+ and
Vim+ expression patterns observed in CTCs from patients
are shown in Fig. 1.
In the 46 NSCLC patients, CK+/EpCAM+ cell types were
found in 3/46 (6.5%) patients’ samples (range 1–4 cells/sample) (Fig. 2). Surprisingly, none of the CTCs were positive
for PD-L1 expression. However, all patients had a proportion
of their WBCs expressing PD-L1 (Figure S1). Cells expressing only vimentin (CK−/EpCAM−/Vim+) with negative for
CD45/16 expression were found in 13/46 (28.3%) samples

with most tumour biopsies (65.2%) expressing PD-L1 in 1%
or more of tumour cells.

Enrichment and detection of CTCs
All enriched samples had two rounds of immunofluorescence staining for CTC characterisation. CTCs were initially identified as CK+/EpCAM+, DAPI+, CD45−/16−, and
with or without PD-L1 expression. The fluorophores were
quenched using borohydride and the samples were re-stained

Merged

DAPI

CD45/16

CK/EpCAM

PD-L1

N-Cad

Vimentin

Single CK+/EpCAM+ CTC with WBCs

Clustered CK-/EpCAM-/Vim+ CTCs with WBCs

Single CK-/EpCAM-/Vim+ CTCs

Quenching &
re-staining

PD-L1+ WBC

PD-L1- WBC

Vim+ WBC

(white) to identify and characterise classical NSCLC CTCs, followed
by fluorescence quenching and re-staining with antibodies for N-cadherin (cyan) and vimentin (pink). Scale bar represents 10 μm

Fig. 1  Representative fluorescence images of cells enriched with
the Parsortix system. Cells were stained with antibodies for pancytokeratins and EpCAM (green), CD45 and CD16 (red), and PD-L1
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Number of circulating cells

30

Clustered CTCs

0
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*

33

40

Samples (n=46)

Fig. 2  CTC counts in NSCLC patients. Blood samples collected
before commencing treatment were enriched for CTCs using the Parsortix system (n = 46). The number of cells on each sample is indi-
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(range 1–33 cells/sample). None of the patient samples
had detectable hybrid CK+/EpCAM+/Vim+ CTCs. Of the
16 patients with detectable CTCs, 50% had CTC clusters
all of which were vimentin-positive only. The number of
cells within clusters ranged from 2 to 10 cells. All the CK+/
EpCAM+ cells were present as single cells. None of the analysed patients’ samples had both C
 K+/EpCAM+ and V
 im+
cell types. Overall, a total of 169 CTCs (range 1–33) were
detected in 16/46 (34.8%) patients’ samples (Fig. 2).

Copy number alteration analysis of detected
circulating cells from NSCLC patients
To confirm the malignancy of the V
 im+ putative CTCs found
as clusters or single cells, we utilised WGA and LP-WGS
Merged

DAPI

CK/EpCAM

CD45/16

N-Cad

PD-L1

to detect chromosomal CNAs. Additionally, EpCAM+/CK+
CTCs found in patients 1467 and 1500 were also analysed.
Overall, we obtained genomic profiles from a total of 13
CTCs or CTC clusters (Figs. 3, 4). In addition, four WBCs
were also analysed as negative controls of any potential artifacts during the WGA (Figure S2). Patient 1467 had four
classical CK+/EpCAM+ CTCs detected, which were picked
and analysed for CNA (Fig. 3). Three of the CTCs displayed
multiple CNAs and similar profiles despite some heterogeneity between cells. One of the four CTCs had low-quality
sequencing and CNAs were not assessable (Fig. 3, CTC 4).
The morphology of this cell suggests that it is undergoing
apoptosis or has been damaged.
We also analysed the genomic profiles of single and clusters of putative CTCs identified via vimentin expression
Vimentin

P-1467 CTC 1

Quenching &
re-staining

P-1467 CTC 2

P-1467 CTC 3

1

3

2

4

5

7

6

P-1467 CTC 4

8

9 10 11 12 13

14

15

16

17 19 21 X Y
18 20 22

Fig. 3  CNA profiles of epithelial CTCs. Immunostaining and morphology of C
 K+/EpCAM+ CTCs in relation to their CNA profiles obtained
from low-pass whole-genome sequencing. Blue lines indicate copy gains and red lines copy number losses

Merged

DAPI

CK/EpCAM

CD45/16

PD-L1

N-Cad

Vimentin

P-1476 Vim 1

P-1476 Vim 2

P-1472 Vim 3

P-1472 Vim 4

Quenching &
re-staining

P-1383 Vim 5

P-1321 Vim 6

P-1321 Vim 7

P-1321 Vim 8

1

2

3

4

5

6

7

8 9 10 11 12 13 14 15 17 19 21 X Y
16 18 20 22

Fig. 4  CNA profiles of mesenchymal CTCs. Immunostaining and morphology of vimentin-expressing CTCs in relation to their CNA profiles
obtained from low-pass whole-genome sequencing. Blue lines indicate copy gains and red lines copy number losses
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a
Prescence of Vim(+) CTCs

No
Yes

N
27
13

%
Median
95%CI
54.5
14.5
5.8 – 23.1
45.5
4.9
0.8 – 9.1
P (log-rank) = 0.090

b
Prescence of Vim(+) CTCs

No
Yes

N
27
13

%
Median
95%CI
71.4
6.2
3.4 – 8.9
28.6
4.6
0.3 – 8.8
P (log-rank) = 0.340

Fig. 5  Kaplan–Meier curves for OS (a) and PFS (b) of patients with and without vimentin-expressing–Vim( +) CTCs. Log-rank p values, group
numbers, percentages, median, and 95% CIs are indicated for each plot

(Fig. 4). These Vim+ cells displayed heterogeneous chromosomal CNA distribution patterns. The two single cells
isolated from 1476 displayed similar CNA profiles, while
the two clusters from 1472 were distinct. Only one cluster of
two cells was analysed from 1383, and it was found to have
CNAs. Finally, three clusters of Vim + cells were obtained
from 1321; two of the clusters showed CNAs while the third
displayed a ‘flat’ normal diploid CNA profile comparable
to WBC controls (Figure S2). Notably, the third cluster of
Vim + cells displayed a distinct spindle morphology (Fig. 4,
Vim 8).

Survival analysis
We analysed the association of patient characteristics and
CTC counts with clinical outcomes, OS, and PFS in participants with a minimum of 6 months of follow-up time and
Table 2  Association of patients’
characteristics with clinical
outcomes of treatment-naïve
NSCLC patients

that were treated with systemic therapies (n = 40). A threshold of one V
 im+CTC was used for survival analysis because
of the low number of detected CTCs. The median follow-up
for OS and PFS for the cohort were 12.3 months (95% CI
9.5–20.9) and 12.2 months (95% CI: 9.4–17.7), respectively.
Log-rank survival analysis showed similar median PFS for
patients with ≥ 1 Vim+ CTCs compared to patients without Vim+ CTCs. However, patients with ≥ 1 Vim+ CTCs
had a median OS of 4.9 months compared to 14.5 months
observed for those with no Vim+ CTCs (Fig. 5).
Cox regression models again showed no difference in
PFS (HR = 1.42, 95% CI 0.68 to − 2.94, p = 0.341), while
Vim+ CTCs was associated with worse OS (HR = 1.98, 95%
CI 0.89–4.45, p = 0.096), albeit not statistically significant
(Fig. 5 and Table 2). There were no statistically significant
associations of the patients' demographics with clinical
outcomes, with regard to age, sex, ECOG status, stage of

Variables

Sex—female vs. male
Age (years)—< 70 vs. ≥ 70
ECOG performance status—0 vs. ≥ 1
Histological type—SCC vs. ADC
Stage—M1a/b vs. M1c
Treatment—IO vs. Chemo + IO
Tumour PD-L1 expression (%)—0 vs. ≥ 1
Vim+CTC—No vs. Yes

OS

PFS

HR (95% CI)

P value

HR (95% CI)

P value

0.87 (0.39–1.98)
1.00 (0.45–2.25)
1.66 (0.72–3.82)
1.01 (0.39–2.58)
1.56 (0.64–3.29)
1.40 (0.58–3.39)
0.91 (0.37–2.21)
1.98 (0.89–4.45)

0.756
0.995
0.232
0.985
0.366
0.458
0.838
0.096

0.75 (0.36–1.57)
1.51 (0.71–3.20)
1.79 (0.83–3.87)
0.82 (0.38–1.76)
1.31 (0.64–2.68)
1.10 (0.53–2.31)
0.84 (0.38–1.85)
1.42 (0.68–2.94)

0.449
0.282
0.135
0.610
0.463
0.792
0.669
0.341

P < 0.05 indicates statistical significance
ECOG Eastern Cooperative Group, SCC squamous cell carcinoma, ADC adenocarcinoma, OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval
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disease, tumour PD-L1 expression, and histological type
(Table 2).

Discussion
Currently, the EpCAM/CK-dependent CellSearch system
remains the only FDA-approved CTC enumeration platform. However, this system fails to recognise CTCs that have
downregulated epithelial markers while undergoing EMT.
This leads to an underestimation of the CTCs undergoing
EMT with hybrid or mesenchymal phenotypes (Yin et al.
2015; Yu et al. 2015).
Our study employed the Parsortix system for CTC enrichment and an immunofluorescence protocol that combines
both epithelial and mesenchymal markers for CTC identification. Our detection rate (34.8%) was considerably lower
than those obtained in most of the previous studies that used
the Parsortix system. Janning et al. reported a detection rate
of 61% (Janning et al. 2019), and Papadaki et al., detected
CTCs in 60% of total patients (Papadaki et al. 2020). However, the observed detection in this study was similar in comparison to a study by Mondelo-Macia et al., who reported
a CTC detection rate of 35% in metastatic NSCLC patients
using the Parsortix (Mondelo‐Macía et al. 2021). These previous studies used CK and EpCAM expression as positive
markers and CD45 expression as the only negative WBC
marker for CTCs. This restricted definition of CTCs does not
take into account the variation in WBCs in the bloodstream
with little or absent CD45 expression such as neutrophils
(Gorczyca et al. 2011). Compounding the issue to a higher
extent is the evidence that neutrophils stain positive for CK
(Schehr et al. 2016; Streicher et al. 1998), raising concerns
about the specificity of the traditional definition of CTCs.
Beyond CD45, this study used CD16 for WBC identification, which has been found to significantly reduce the number of false positive CTCs (Swennenhuis et al. 2016; Spencer 2020). These factors may explain the low CTC detection
rate in our study when compared to others.
One unanticipated finding was that in our cohort none of
the detected NSCLC CTCs had PD-L1 expression, despite
65.2% of the cohort having PD-L1-positive tumours (> 1%),
with 36.5% with more than 50% tumour specific staining.
Published studies have consistently reported wide ranges
of the rate of PD-L1 expressing CTCs, from 8 to 100%, in
NSCLC (Acheampong et al. 2020; Kong et al. 2021; Ouyang
et al. 2021). Detection of PD-L1 expression is influenced
by a range of different factors including different antibodies, cut-off values, and CTC isolation platforms (Ouyang
et al. 2021; Acheampong et al. 2020). Nevertheless, we
detected PD-L1 expression on a subset of WBCs present in
the enriched samples which is consistent with reports from
previous studies (Ilié et al. 2018; Kotsakis et al. 2019).

EpCAM and different members of the cytokeratin
family are frequently utilised for CTC identification
before subsequent characterisation due to the epithelial
nature of NSCLC (Hamilton and Rath 2016). Interestingly, the majority of the detected circulating cells in this
study expressed vimentin with total loss of EpCAM and
cytokeratin. More precisely, many of these V
 im+ cells had
cytomorphological characteristics such as shape and size
consistent with CTCs, in addition to being negative for
WBC markers (Boffa et al. 2017). Moreover, all putative
NSCLC CTCs in this study were negative for N-cadherin.
Since these identified circulating cells do not meet the field
consensus criteria for CTCs, due to their lack of CK we
assessed the neoplastic origin of these Vim+ cells together
with CK+/EpCAM+ CTCs by LP-WGS analysis.
Classical CTCs presented with significant genomic
alterations with some degree of heterogeneity. Among the
Vim+ cells, those presenting CNAs could be considered
bona fide CTCs. Our findings are in line with a previous
study by Xu et al. who identified V
 im+ circulating cells in
metastatic prostate cancer patients using the Parsortix and
confirmed their malignancy by genomic alterations (Xu
et al. 2017). Another study by Reduzzi et al. demonstrated
that enriched circulating cells lacking both epithelial and
leukocyte marker expression presented altered CNA profiles and thus were defined as CTCs (Reduzzi et al. 2020).
Because the authors only identified double negative cells
for the CNA analysis, the actual phenotype of these cells
was unknown. By contrast, our putative CTCs were phenotypically identified to be V
 im+/CK− cells (Reduzzi et al.
2020). These reports together indicate the relevance of
the existence of CTCs subpopulations that express low or
no EpCAM or CK and can escape detection by epithelial
isolation methods and markers.
It is also worth noting that some Vim + cells did not
carry CNA and were, therefore, classified as non-tumourigenic mesenchymal-derived circulating cells. Vimentin
is also expressed in circulating endothelial cells, which
have been shown to also increase in cancer patients (Chen
et al. 2021; Lin et al. 2017). The presence of hematopoietic cells of mesenchymal origin and reactive stromal
cells compromise the specificity for recognition of CTCs
via mesenchymal markers (Stoecklein et al. 2016; Schehr
et al. 2016; Cima et al. 2016; Plaks et al. 2013). Preferably, additional exclusion markers should be included in
future panels. Cancer patients have been shown to have an
increased number of circulating endothelial cells (CECs)
that are probably shed from tumour angiogenesis-associated processes or damaged tumour vessel walls (Ilie et al.
2014). Therefore, immunoassays for CTCs should include
markers such as CD31, CD34, and CD144 to exclude cells
of endothelial origin (Magbanua et al. 2015; Bidard et al.
2010).
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The prognostic value of vimentin expression in various
cancers has been well documented in the literature (Santamaria et al. 2017; Dongre and Weinberg 2019). High levels
of vimentin expression are associated with poor survival in
patients with NSCLC (Ye et al. 2016). Although our survival analyses in patients with V
 im+ CTCs did not achieve
statistically significant levels, they showed a trend towards
unfavourable OS. A previous study by Zhang et al. indicated
mesenchymal CTCs identified NSCLC patients with distant
metastasis (Zhang et al. 2019).
Our study employed a robust CTC isolation, identification, and downstream single-cell genomic analysis. Nonetheless, some limitations need to be mentioned. The sample
size of the study was small. We were not able to compare
the CNA profiles of NSCLC CTCs to that of the matching
tumours as samples were not available for profiling. Moreover, some Vim+ cells collected could not be used for CNA
analysis due to unsuccessful amplification. This may have
been caused by the method used to fix and immunostained
the cells, which may have compromised the quality of the
nucleus, or our inability to effectively recover the nuclei
using the micromanipulator (CellCelector).

Conclusion
Overall, these results reveal that pCK negative, EpCAM
negative, and vimentin expressing cells represent a large
proportion of CTCs detected in NSCLC patients. These cells
would be commonly missed by standard CTC categorisation.
The presence of CNAs confirmed the neoplastic nature of
a proportion of vimentin-only expressing cells. The lack of
CNA in some of the CK− Vim+ cells underscores the need
for better markers to identify and quantify CTCs. Future
longitudinal studies with larger cohorts are needed to validate the clinical validity of epitope-independent microfluidic
technologies for CTC isolation and the consideration of the
addition of Vim+ CTCs to the classical CTC definition in
NSCLC and evaluation of their prognostic value.
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